Irritable Bowel Syndrome Market by Type and Product - Global Industry Analysis & Forecast to 2027
Published On : July 2019 Pages : 150 Category: Pharma & Healthcare Report Code : HC084538
Irritable Bowel Syndrome Market by Type (IBS-D, IBS-C) Product (Amitiza, Xifaxan, Viberzi, Linzess/Constella, Other Products) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Irritable Bowel Syndrome Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Irritable bowel syndrome is a useful gastrointestinal issue of gut that might be portrayed by colon muscle withdrawals. Irritable bowel syndrome influences the internal organ. Irritable bowel syndrome is related with breaking down of the entrail and significantly happens in senior populace.
Drivers and Restraints
The market of touchy gut disorder treatment is seeing positive development attributable to foundation of well-characterized diagnosis criteria and investigation of novel remedial classes by the key market players. Moreover, change in way of life and dietary patterns builds the frequency of this issue may raise the usage of this treatment and henceforth drive the market development.
Regional Insights
North America was the biggest income producing district in 2018 and is anticipated to show a similar pattern over the gauge time frame.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Ardelyx
- Ironwood Pharmaceuticals, Inc.
- Synthetic Biologics, Inc.
- Allergan
- Synergy Pharmaceuticals In.
- Astellas Pharma, Inc.
- Bausch Health
- Takeda Pharmaceutical Company Limited
- AstraZeneca
- Sebela Pharmaceuticals Inc.
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
o Irritable Bowel Syndrome Treatment Market, By Type, Estimates and Forecast, 2017-2027 ($Million)
o IBS-D
o IBS-C
o Irritable Bowel Syndrome Treatment Market, By Product, Estimates and Forecast, 2017-2027 ($Million)
o Amitiza
o Xifaxan
o Viberzi
o Linzess/Constella
o Other Products
o Irritable Bowel Syndrome Treatment Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Ardelyx
o Ironwood Pharmaceuticals, Inc.
o Synthetic Biologics, Inc.
o Allergan
o Synergy Pharmaceuticals In.
o Astellas Pharma, Inc.
o Bausch Health
o Takeda Pharmaceutical Company Limited
o AstraZeneca
o Sebela Pharmaceuticals Inc.
o Irritable Bowel Syndrome Treatment Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Irritable Bowel Syndrome Treatment Market , By Country
o U.S. Irritable Bowel Syndrome Treatment Market
o Canada Irritable Bowel Syndrome Treatment Market
o Mexico Irritable Bowel Syndrome Treatment Market
o Europe
§ Europe Irritable Bowel Syndrome Treatment Market , By Country
o Germany Irritable Bowel Syndrome Treatment Market
o UK Irritable Bowel Syndrome Treatment Market
o France Irritable Bowel Syndrome Treatment Market
o Russia Irritable Bowel Syndrome Treatment Market
o Italy Irritable Bowel Syndrome Treatment Market
o Rest of Europe Irritable Bowel Syndrome Treatment Market
o Asia-Pacific
§ Asia-Pacific Irritable Bowel Syndrome Treatment Market , By Country
o China Irritable Bowel Syndrome Treatment Market
o Japan Irritable Bowel Syndrome Treatment Market
o South Korea Irritable Bowel Syndrome Treatment Market
o India Irritable Bowel Syndrome Treatment Market
o Southeast Asia Irritable Bowel Syndrome Treatment Market
o Rest of Asia-Pacific Irritable Bowel Syndrome Treatment Market
o South America
§ South America Irritable Bowel Syndrome Treatment Market , By Country
o Brazil Irritable Bowel Syndrome Treatment Market
o Argentina Irritable Bowel Syndrome Treatment Market
o Columbia Irritable Bowel Syndrome Treatment Market
o Rest of South America Irritable Bowel Syndrome Treatment Market
o Middle East and Africa
§ Middle East and Africa Irritable Bowel Syndrome Treatment Market , By Country
o Saudi Arabia Irritable Bowel Syndrome Treatment Market
o UAE Irritable Bowel Syndrome Treatment Market
o Egypt Irritable Bowel Syndrome Treatment Market
o Nigeria Irritable Bowel Syndrome Treatment Market
o South Africa Irritable Bowel Syndrome Treatment Market
o Rest of MEA Irritable Bowel Syndrome Treatment Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Irritable Bowel Syndrome Treatment Market, By Type
5.1. Introduction
5.2. Global Irritable Bowel Syndrome Treatment Revenue and Market Share by Type (2017-2027)
5.2.1. Global Irritable Bowel Syndrome Treatment Revenue and Revenue Share by Type (2017-2027)
5.3. IBS-D
5.3.1. Global IBS-D Revenue and Growth Rate (2017-2027)
5.4. IBS-C
5.4.1. Global IBS-C Revenue and Growth Rate (2017-2027)
6. Irritable Bowel Syndrome Treatment Market, By Product
6.1. Introduction
6.2. Global Irritable Bowel Syndrome Treatment Revenue and Market Share by Product (2017-2027)
6.2.1. Global Irritable Bowel Syndrome Treatment Revenue and Revenue Share by Product (2017-2027)
6.3. Amitiza
6.3.1. Global Amitiza Revenue and Growth Rate (2017-2027)
6.4. Xifaxan
6.4.1. Global Xifaxan Revenue and Growth Rate (2017-2027)
6.5. Viberzi
6.5.1. Global Viberzi Revenue and Growth Rate (2017-2027)
6.6. Linzess/Constella
6.6.1. Global Linzess/Constella Revenue and Growth Rate (2017-2027)
6.7. Other Products
6.7.1. Global Other Products Revenue and Growth Rate (2017-2027)
7. Irritable Bowel Syndrome Treatment Market, By Region
7.1. Introduction
7.2. Global Irritable Bowel Syndrome Treatment Revenue and Market Share by Regions
7.2.1. Global Irritable Bowel Syndrome Treatment Revenue by Regions (2017-2027)
7.3. North America Irritable Bowel Syndrome Treatment by Countries
7.3.1. North America Irritable Bowel Syndrome Treatment Revenue and Growth Rate (2017-2027)
7.3.2. North America Irritable Bowel Syndrome Treatment Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Irritable Bowel Syndrome Treatment by Countries
7.4.1. Europe Irritable Bowel Syndrome Treatment Revenue and Growth Rate (2017-2027)
7.4.2. Europe Irritable Bowel Syndrome Treatment Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific Irritable Bowel Syndrome Treatment by Countries
7.5.1. Asia-Pacific Irritable Bowel Syndrome Treatment Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Irritable Bowel Syndrome Treatment Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America Irritable Bowel Syndrome Treatment by Countries
7.6.1. South America Irritable Bowel Syndrome Treatment Revenue and Growth Rate (2017-2027)
7.6.2. South America Irritable Bowel Syndrome Treatment Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa Irritable Bowel Syndrome Treatment by Countries
7.7.1. Middle East and Africa Irritable Bowel Syndrome Treatment Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Irritable Bowel Syndrome Treatment Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. Ardelyx
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Ironwood Pharmaceuticals, Inc.
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Synthetic Biologics, Inc.
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Allergan
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Synergy Pharmaceuticals In.
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. Astellas Pharma, Inc.
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. Bausch Health
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. Takeda Pharmaceutical Company Limited AstraZeneca
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. AstraZeneca
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
8.10. Sebela Pharmaceuticals Inc.
8.10.1. Business Overview
8.10.2. Service Portfolio
8.10.3. Strategic Developments
8.10.4. Financial Overview
9. Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.1. Global Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
9.2. Irritable Bowel Syndrome Treatment Market Forecast by Regions (2017-2027)
9.2.1. North America Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.1.1. United States Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.1.2. Canada Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.1.3. Mexico Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.2. Europe Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.2.1. Germany Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.2.2. France Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.2.3. UK Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.2.4. Russia Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.2.5. Italy Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.2.6. Rest of Europe Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.3. Asia-Pacific Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.3.1. China Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.3.2. Japan Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.3.3. Korea Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.3.4. India Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.3.5. Southeast Asia Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.3.6. Rest of Asia-Pacific Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.4. South America Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.4.1. Brazil Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.4.2. Argentina Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.4.3. Columbia Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.4.4. Rest of South America Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.5. Middle East and Africa Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.5.1. Saudi Arabia Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.5.2. United Arab Emirates Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.5.3. Egypt Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.5.4. Nigeria Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.5.5. South Africa Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.5.6. Turkey Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.2.5.7. Rest of Middle East and Africa Irritable Bowel Syndrome Treatment Market Forecast (2017-2027)
9.3. Irritable Bowel Syndrome Treatment Market Forecast by Type (2017-2027)
9.3.1. Irritable Bowel Syndrome Treatment Forecast by Type (2017-2027)
9.3.2. Irritable Bowel Syndrome Treatment Market Share Forecast by Type (2017-2027)
9.4. Irritable Bowel Syndrome Treatment Market Forecast by Product (2017-2027)
9.4.1. Irritable Bowel Syndrome Treatment Forecast by Product (2017-2027)
9.4.2. Irritable Bowel Syndrome Treatment Market Share Forecast by Product (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Irritable Bowel Syndrome Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Irritable Bowel Syndrome Treatment Revenue and Revenue Share by Type (2017-2018)
Figure Global IBS-D Revenue and Growth Rate (2017-2018)
Figure Global IBS-C Revenue and Growth Rate (2017-2018)
Table Global Irritable Bowel Syndrome Treatment Revenue and Revenue Share by Product (2017-2018)
Figure Global Amitiza Revenue and Growth Rate (2017-2018)
Figure Global Xifaxan Revenue and Growth Rate (2017-2018)
Figure Global Viberzi Revenue and Growth Rate (2017-2018)
Figure Global Linzess/Constella Revenue and Growth Rate (2017-2018)
Figure Global Other Products Revenue and Growth Rate (2017-2018)
Table Global Irritable Bowel Syndrome Treatment Revenue by Regions (2017-2018)
Figure North America Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure North America Irritable Bowel Syndrome Treatment Revenue and Growth Rate (2017-2018)
Figure North America Irritable Bowel Syndrome Treatment by Countries (2017-2018)
Figure North America Irritable Bowel Syndrome Treatment Revenue (Million USD) by Countries (2017-2018)
Figure United States Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure United States Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure Canada Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure Mexico Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure Europe Irritable Bowel Syndrome Treatment Revenue and Growth Rate (2017-2018)
Figure Europe Irritable Bowel Syndrome Treatment by Countries (2017-2018)
Figure Europe Irritable Bowel Syndrome Treatment Revenue (Million USD) by Countries (2017-2018)
Figure Germany Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure Germany Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure France Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure UK Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure Russia Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure Italy Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure Rest of Europe Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure Asia-Pacific Irritable Bowel Syndrome Treatment Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Irritable Bowel Syndrome Treatment by Countries (2017-2018)
Figure Asia-Pacific Irritable Bowel Syndrome Treatment Revenue (Million USD) by Countries (2017-2018)
Figure China Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure China Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure Japan Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure Korea Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure India Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure Southeast Asia Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure South America Irritable Bowel Syndrome Treatment Revenue and Growth Rate (2017-2018)
Figure South America Irritable Bowel Syndrome Treatment by Countries (2017-2018)
Figure South America Irritable Bowel Syndrome Treatment Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure Brazil Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure Argentina Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure Columbia Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure Rest of South America Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure Middle East and Africa Irritable Bowel Syndrome Treatment Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Irritable Bowel Syndrome Treatment by Countries (2017-2018)
Figure Middle East and Africa Irritable Bowel Syndrome Treatment Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure Saudi Arabia Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure United Arab Emirates Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure Egypt Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure Nigeria Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure South Africa Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure Turkey Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Irritable Bowel Syndrome Treatment Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Table Ardelyx Irritable Bowel Syndrome Treatment Financial Overview
Table Ironwood Pharmaceuticals, Inc. Irritable Bowel Syndrome Treatment Financial Overview
Table Synthetic Biologics, Inc. Irritable Bowel Syndrome Treatment Financial Overview
Table Allergan Irritable Bowel Syndrome Treatment Financial Overview
Table Synergy Pharmaceuticals In. Irritable Bowel Syndrome Treatment Financial Overview
Table Astellas Pharma, Inc. Irritable Bowel Syndrome Treatment Financial Overview
Table Bausch Health Irritable Bowel Syndrome Treatment Financial Overview
Table Takeda Pharmaceutical Company Limited AstraZeneca Irritable Bowel Syndrome Treatment Financial Overview
Table AstraZeneca Irritable Bowel Syndrome Treatment Financial Overview
Table Sebela Pharmaceuticals Inc. Irritable Bowel Syndrome Treatment Financial Overview
Figure Global Irritable Bowel Syndrome Treatment Revenue (Millions USD) and Growth Rate (2018-2025)
Table Irritable Bowel Syndrome Treatment Market Forecast by Regions (2018-2025)
Figure North America Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure United States Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure Canada Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure Mexico Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure Europe Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure Germany Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure France Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure UK Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure Russia Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure Italy Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure Rest of Europe Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure Asia-Pacific Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure China Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure Japan Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure Korea Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure India Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure Southeast Asia Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure South America Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure Brazil Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure Argentina Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure Columbia Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure Rest of South America Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure Middle East and Africa Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure Saudi Arabia Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure United Arab Emirates Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure Egypt Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure Nigeria Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure South Africa Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure Turkey Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Irritable Bowel Syndrome Treatment Market Forecast (2018-2025)
Figure Global Irritable Bowel Syndrome Treatment Forecast by Type (2018-2025)
Figure Global Irritable Bowel Syndrome Treatment Market Share Forecast by Type (2018-2025)
Figure Global Irritable Bowel Syndrome Treatment Forecast by Type (2018-2025)
Figure Global Irritable Bowel Syndrome Treatment Forecast by Product (2018-2025)
Figure Global Irritable Bowel Syndrome Treatment Market Share Forecast by Product (2018-2025)
Figure Global Irritable Bowel Syndrome Treatment Forecast by Product (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|